No benefit seen for rechallenge with nivolumab after progression in the post-immune checkpoint inhibitor setting.

Toni Choueiri, MD, discusses the rationale behind the drug combination of tivozanib and nivolumab in the TiNivo-2 study.

Fotivda monotherapy may show better outcomes in second-line therapy than the combination of Opdivo and Fotivda in metastatic ...

We are working with Guy’s and St. Thomas’ NHS Foundation Trust to produce national standardised SACT regimen-specific consent forms. We want to support clinicians in ensuring all patients are fully ...

NSCLC, adding nivolumab to tivozanib in metastatic RCC underwhelms, and T-DXd shows improvement in HER2+ breast cancer with brain metastases.

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as ...

For patients with metastatic renal cell carcinoma (mRCC) and progression during or after one to two prior lines of therapy, ...

Research presented at ESMO 2024 could have practice-changing implications for breast, gastrointestinal, genitourinary, and gynecologic cancers.

In this interview, Toni K. Choueiri, MD, shares the background and key findings from the study, “Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or ...

AVEO Oncology, an LG Chem company ("AVEO"), announced today that the TiNivo-2 Phase 3 clinical trial results in patients with ...

Dr. Choueiri comments, “The PFS results in the intent-to-treat population demonstrate the activity of tivozanib in the 2 nd and 3 rd lines following front line immunotherapy. The safety results were ...

Clinical outcomes were not improved when nivolumab (Opdivo) was added to tivozanib (Fotivda) for the treatment of patients with metastatic renal cell carcinoma (RCC) whose disease progressed on or ...